Neuroprotective effect of cilostazol against retinal ischemic damage via inhibition of leukocyte-endothelial cell interactions

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 4, 2007, Pages 818-825

  Iwama, D ^a   Miyamoto, Kazuaki ^a   Miyahara, S ^a   Tamura, H ^a   Tsujikawa, A ^a   Yamashiro, K ^b   Kiryu, J ^c   Yoshimura, N ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Endothelial cells; Ischemia; Leukocytes; Platelets; Retina

Indexed keywords

CILOSTAZOL; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; PADGEM PROTEIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL FUNCTION; CELL INTERACTION; CONTROLLED STUDY; ENDOTHELIUM CELL; EX VIVO STUDY; FLUORESCENCE MICROSCOPY; HISTOPATHOLOGY; IN VIVO STUDY; LEUKOCYTE; LEUKOCYTE COUNT; MALE; MICROCIRCULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RETINA BLOOD FLOW; RETINA ISCHEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCANNING LASER OPHTHALMOSCOPY; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD PLATELETS; CELL COMMUNICATION; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; ISCHEMIA; LEUKOCYTE ROLLING; LEUKOCYTES; MALE; NEUROPROTECTIVE AGENTS; PLATELET ADHESIVENESS; RATS; RATS, SPRAGUE-DAWLEY; RETINAL VESSELS; TETRAZOLES;

EID: 34147105577     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02425.x     Document Type: Article

References (35)

1. Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J. Cilostazol (pletal): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 2001; 19: 369-86.
2. Dawson DL, Cutler BS, Meissner MH, Strandness Jr DE. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98: 678-86.
3. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147-57.
4. Ge J, Han Y, Jiang H, Sun B, Chen J, Zhang S, Du Z. RACTS: A prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: Long-term clinical and angiographic outcome. J Cardiovasc Pharmacol 2005; 46: 162-6.
5. Honda F, Imai H, Ishikawa M, Kubota C, Shimizu T, Fukunaga M, Saito N. Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia. Stroke 2006; 37: 223-8.
6. Kuroda T, Shiohara E, Homma T, Furukawa Y, Chiba S. Effects of leukocyte and platelet depletion on ischemia-reperfusion injury to dog pancreas. Gastroenterology 1994; 107: 1125-34.
7. Massberg S, Enders G, Leiderer R, Eisenmenger S, Vestweber D, Krombach F, Messmer K. Platelet-endothelial cell interactions during ischemia/ reperfusion: The role of P-selectin. Blood 1998; 92: 507-15.
8. Tsujikawa A, Kiryu J, Nonaka A, Yamashiro K, Nishiwaki H, Tojo SJ, Ogura Y, Honda Y. In vivo evaluation of platelet-endothelial interactions in retinal microcirculation of rats. Invest Ophthalmol Vis Sci 1999; 40: 2918-24.
9. Akopov S, Sercombe R, Seylaz J. Cerebrovascular reactivity: Role of endothelium/platelet/leukocyte interactions. Cerebrovasc Brain Metab Rev 1996; 8: 11-94.
10. Piccardoni P, Evangelista V, Piccoli A, de Gaetano G, Walz A, Cerletti C. Thrombin-activated human platelets release two NAP-2 variants that stimulate polymorphonuclear leukocytes. Thromb Haemost 1996; 76: 780-5.
11. Kuijper PH, Gallardo Torres HI, van der Linden JA, Lammers JW, Sixma JJ, Koenderman L, Zwaginga JJ. Platelet-dependent primary hemostasis promotes selectin- and integrin-mediated neutrophil adhesion to damaged endothelium under flow conditions. Blood 1996; 87: 3271-81.
12. El-Beyrouty C, Spinler SA. Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting. Ann Pharmacother 2001; 35: 1108-13.
13. Sluiter W, Pietersma A, Lamers JM, Koster JF. Leukocyte adhesion molecules on the vascular endothelium: Their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression. J Cardiovasc Pharmacol 1993; 22 (Suppl. 4): S37-44.
14. Ito H, Miyakoda G, Mori T. Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation. Platelets 2004; 15: 293-301.
15. Inoue T, Uchida T, Sakuma M, Imoto Y, Ozeki Y, Ozaki Y, Hikichi Y, Node K. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol 2004; 44: 1408-14.
16. Distler C, Bronzel M, Paas I, Wahle P. Biochemical and histological analysis of two Muller cell antibodies in developing and adult cat and rat central nervous system. Cell Tissue Res 1997; 289: 411-26.
17. Greenwood J, Pryce G, Devine L, Male DK, dos Santos WL, Calder VL, Adamson P. SV40 large T immortalised cell lines of the rat blood-brain and blood-retinal barriers retain their phenotypic and immunological characteristics. J Neuroimmunol 1996; 71: 51-63.
18. Tsujikawa A, Ogura Y, Hiroshiba N, Miyamoto K, Kiryu J, Honda Y. In vivo evaluation of leukocyte dynamics in retinal ischemia reperfusion injury. Invest Ophthalmol Vis Sci 1998; 39: 793-800.
19. Miyahara S, Kiryu J, Yamashiro K, Miyamoto K, Hirose F, Tamura H, Katsuta H, Nishijima K, Tsujikawa A, Honda Y. Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. Am J Pathol 2004; 164: 1697-706.
20. Hirose F, Kiryu J, Miyamoto K, Nishijima K, Miyahara S, Katsuta H, Tamura H, Honda Y. In vivo evaluation of retinal injury after transient ischemia in hypertensive rats. Hypertension 2004; 43: 1098-102.
21. Nishijima K, Kiryu J, Tsujikawa A, Honjo M, Nonaka A, Yamashiro K, Tanihara H, Tojo SJ, Ogura Y, Honda Y. In vivo evaluation of platelet-endothelial interactions after transient retinal ischemia. Invest Ophthalmol Vis Sci 2001; 42: 2102-9.
22. Suganami E, Takagi H, Ohashi H, Suzuma K, Suzuma I, Oh H, Watanabe D, Ojima T, Suganami T, Fujio Y, Nakao K, Ogawa Y, Yoshimura N. Leptin stimulates ischemia-induced retinal neovascularization: Possible role of vascular endothelial growth factor expressed in retinal endothelial cells. Diabetes 2004; 53: 2443-8.
23. Raghavendra Rao VL, Bowen KK, Dhodda VK, Song G, Franklin JL, Gavva NR, Dempsey RJ. Gene expression analysis of spontaneously hypertensive rat cerebral cortex following transient focal cerebral ischemia. J Neurochem 2002; 83: 1072-86.
24. Nishijima K, Kiryu J, Tsujikawa A, Honjo M, Nonaka A, Yamashiro K, Kamizuru H, Ieki Y, Tanihara H, Honda Y, Ogura Y. Inhibitory effects of antithrombin III on interactions between blood cells and endothelial cells during retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 2003; 44: 332-41.
25. Choi JM, Shin HK, Kim KY, Lee JH, Hong KW. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 2002; 300: 787-93.
26. Lee TM, Su SF, Tsai CH, Lee YT, Wang SS. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clin Sci (Lond) 2001; 101: 305-11.
27. Duh E, Aiello LP. Vascular endothelial growth factor and diabetes: The agonist versus antagonist paradox. Diabetes 1999; 48: 1899-906.
28. Ikeda U, Ikeda M, Kano S, Kanbe T, Shimada K. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells. Eur J Pharmacol 1996; 314: 197-202.
29. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/ macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992; 23: 1367-79.
30. Ishida S, Yamashiro K, Usui T, Kaji Y, Ogura Y, Hida T, Honda Y, Oguchi Y, Adamis AP. Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med 2003; 9: 781-8.
31. Piguet PF, Vesin C, Ryser JE, Senaldi G, Grau GE, Tacchini-Cottier F. An effector role for platelets in systemic and local lipopolysaccharide-induced toxicity in mice, mediated by a CD11a- and CD54-dependent interaction with endothelium. Infect Immun 1993; 61: 4182-7.
32. Nishio Y, Kashiwagi A, Takahara N, Hidaka H, Kikkawa R. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells. Horm Metab Res 1997; 29: 491-5.
33. Mizutani M, Okuda Y, Yamashita K. Effect of cilostazol on the production of platelet-derived growth factor in cultured human vascular endothelial cells. Biochem Mol Med 1996; 57: 156-8.
34. Buttrum SM, Hatton R, Nash GB. Selectin-mediated rolling of neutrophils on immobilized platelets. Blood 1993; 82: 1165-74.
35. Nishijima K, Kiryu J, Tsujikawa A, Miyamoto K, Honjo M, Tanihara H, Nonaka A, Yamashiro K, Katsuta H, Miyahara S, Honda Y, Ogura Y. Platelets adhering to the vascular wall mediate postischemic leukocyte-endothelial cell interactions in retinal microcirculation. Invest Ophthalmol Vis Sci 2004; 45: 977-84.